Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00994916|
Expanded Access Status : Available
First Posted : October 14, 2009
Last Update Posted : November 7, 2017
|Condition or disease||Intervention/treatment|
|Lambert-Eaton Myasthenic Syndrome||Drug: 3,4 diaminopyridine|
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained.
The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board.
The investigator has a hold on enrolling new subjects.
|Study Type :||Expanded Access|
|Official Title:||Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine|
- Drug: 3,4 diaminopyridine
3,4 diaminopyridine up to 80 mg daily in divided doses
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994916
|Contact: David Lacomis, MDfirstname.lastname@example.org|